北美肺癌筛查市场预测至 2030 年 – 区域分析 – 按癌症类型 [非小细胞肺癌 (NSCLC) 和小细胞肺癌]、技术 [低剂量计算机断层扫描 (LDCT)、胸部 X -射线、液体活检等]、年龄组(50 岁及以上和 50 岁以下)和最终用户(医院、诊断中心等)

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030


No. of Pages: 100    |    Report Code: BMIRE00029064    |    Category: Life Sciences

North America Lung Cancer Screening Market

北美肺癌筛查市场预计将从2022年的9.6541亿美元增长到2030年的18.1148亿美元。预计2022年至2030年复合年增长率为8.2% . 

增加政府支持推动北美肺癌筛查市场。

肺癌是全世界死亡的主要原因之一。肺癌筛查是癌症预防方法的重要组成部分。早期诊断出肺癌患者的预后会更好,因此鼓励肺癌高危人群进行常规检查,以检测肺部癌性生长的形成。据美国癌症协会估计,2023年美国肺癌新发病例约为238,340例;其中,女性 120,790 人,男性 117,550 人。因此,全球肺癌发病率的上升推动了肺癌筛查计划的启动,进而推动了市场增长。

北美肺癌筛查市场概览

北美肺癌筛查市场分为美国、加拿大和墨西哥。该地区的增长归因于多种因素,例如肺癌发病率的增加以及人们对吸烟副作用的认识。此外,政府对筛查的支持不断增加,导致市场进一步增长。

在北美,美国在北美肺癌筛查市场中占有重要份额。该国的市场增长主要是由肺癌发病率上升和政府举措推动的。肺癌是美国男性和女性中第二常见的癌症。根据美国癌症协会的数据,截至 2023 年,美国约有 238,340 名成年人(117,550 名男性和 120,790 名女性)被诊断患有肺癌,约 127,070 名成年人(67,160 名男性和 59,910 名女性)死亡由于疾病。肺癌占所有癌症死亡的五分之一,使其成为美国癌症死亡的主要原因。这些统计数据包括小细胞肺癌和非小细胞肺癌。 NSCLC 是最常见的肺癌类型,占所有肺癌诊断的 81%。在美国,所有类型肺癌的 5 年相对生存率为 23%,对于非小细胞肺癌,男性和女性的 5 年相对生存率分别为 23% 和 33%。在美国,建议通过一种称为低剂量螺旋或螺旋计算机断层扫描(CT 或 CAT)扫描的测试来筛查肺癌。预防服务工作组 (USPSTF) 建议 50 岁至 80 岁、有 20 包或以上吸烟史或在过去 15 年内戒烟的人每年应进行低剂量 CT 扫描筛查肺癌。根据数字战略办公室管理的白宫官方网站 Whitehouse.gov 于 2023 年 5 月发布的报告,社区癌症中心协会 (ACCC) 和阿斯利康正在建立合作伙伴关系,以开发和实施通过“农村阿巴拉契亚肺癌筛查计划”,采用以人为本的可持续方法来增加美国农村地区的肺癌筛查。阿巴拉契亚地区(包括整个西弗吉尼亚州和其他 12 个州的部分地区)的癌症死亡率比美国其他地区高 10%。该计划的目标是将肺癌的五年生存率提高一倍。此类举措正在促进美国北美肺癌筛查市场的增长。

北美肺癌筛查市场到 2030 年的收入和预测(百万美元)

北美肺癌筛查市场细分< /strong>

北美肺癌筛查市场按癌症类型、技术、年龄组、最终用户和国家/地区进行细分。

根据癌症类型,北美肺癌筛查市场分为非小细胞肺癌 (NSCLC) 和小细胞肺癌。 2022年,非小细胞肺癌(NSCLC)细分市场在北美肺癌筛查市场中占据更大份额。

基于技术,北美肺癌筛查筛查市场分为胸部 X 光检查、低剂量计算机断层扫描 (LDCT)、液体活检等。 2022 年,低剂量计算机断层扫描 (LDCT) 细分市场在北美肺癌筛查市场中占据最大份额。

根据年龄组,北美肺癌筛查市场为细分为 50 岁及以上和 50 岁以下。2022 年,50 岁及以上细分市场在北美肺癌筛查市场中占据较大份额。

根据最终用户,北美肺癌筛查市场分为医院、诊断中心等。 2022年,医院细分市场在北美肺癌筛查市场中占据最大份额。

按国家/地区划分,北美肺癌筛查市场分为美国、加拿大和墨西哥。 2022 年,美国在北美肺癌筛查市场占据主导地位。

Siemens AG、Koninklijke Philips NV、Canon Inc、Medtronic、GE HealthCare、Nuance Communications Inc、LungLife AI, Inc、Intelerad Medical Systems、bioAffinity Technologies, Inc 和 CSV Health 是北美肺癌筛查市场上的一些领先公司。



North America Lung Cancer Screening Strategic Insights

Strategic insights for North America Lung Cancer Screening involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/north-america-lung-cancer-screening-market-strategic-framework.webp
Get more information on this report

North America Lung Cancer Screening Report Scope

Report Attribute Details
Market size in 2022 US$ 965.41 Million
Market Size by 2030 US$ 1,811.48 Million
Global CAGR (2022 - 2030) 8.2%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 癌症类型
  • 非小细胞肺癌
  • 小细胞肺癌
By 技术
  • 低剂量计算机断层扫描
  • 胸部X光
  • 液体活检
By 年龄组
  • 50 岁以上和 50 岁以下
By 最终用户
  • 医院
  • 诊断中心
Regions and Countries Covered 北美
  • 美国
  • 加拿大
  • 墨西哥
Market leaders and key company profiles
  • bioAffinity Technologies, Inc
  • Canon Medical Systems Corp
  • CVS Health
  • GE HealthCare Technologies Inc
  • Intelerad Medical Systems Incorporated
  • Koninklijke Philips NV
  • LungLife AI, Inc
  • Medtronic Plc
  • Nuance Communications Inc
  • Siemens AG
  • Get more information on this report

    North America Lung Cancer Screening Regional Insights

    The regional scope of North America Lung Cancer Screening refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/north-america-lung-cancer-screening-market-geography.webp
    Get more information on this report

    The List of Companies - North America Lung Cancer Screening Market

    1. bioAffinity Technologies, Inc
    2. Canon Medical Systems Corp
    3. CVS Health
    4. GE HealthCare Technologies Inc
    5. Intelerad Medical Systems Incorporated
    6. Koninklijke Philips NV
    7. LungLife AI, Inc
    8. Medtronic Plc
    9. Nuance Communications Inc
    10. Siemens AG
    Frequently Asked Questions
    How big is the North America Lung Cancer Screening Market?

    The North America Lung Cancer Screening Market is valued at US$ 965.41 Million in 2022, it is projected to reach US$ 1,811.48 Million by 2030.

    What is the CAGR for North America Lung Cancer Screening Market by (2022 - 2030)?

    As per our report North America Lung Cancer Screening Market, the market size is valued at US$ 965.41 Million in 2022, projecting it to reach US$ 1,811.48 Million by 2030. This translates to a CAGR of approximately 8.2% during the forecast period.

    What segments are covered in this report?

    The North America Lung Cancer Screening Market report typically cover these key segments-

  • 癌症类型 (非小细胞肺癌, 小细胞肺癌)
  • 技术 (低剂量计算机断层扫描, 胸部X光, 液体活检)
  • 年龄组 (50 岁以上和 50 岁以下)
  • What is the historic period, base year, and forecast period taken for North America Lung Cancer Screening Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Lung Cancer Screening Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
  • Who are the major players in North America Lung Cancer Screening Market?

    The North America Lung Cancer Screening Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • bioAffinity Technologies, Inc
  • Canon Medical Systems Corp
  • CVS Health
  • GE HealthCare Technologies Inc
  • Intelerad Medical Systems Incorporated
  • Koninklijke Philips NV
  • LungLife AI, Inc
  • Medtronic Plc
  • Nuance Communications Inc
  • Siemens AG
  • Who should buy this report?

    The North America Lung Cancer Screening Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the North America Lung Cancer Screening Market value chain can benefit from the information contained in a comprehensive market report.